ePrints

Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?

Lookup NU author(s): Professor Catharien Hilkens, Professor John IsaacsORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Dendritic cells with tolerogenic function (tolDC) have become a promising immunotherapeutic tool for reinstating immune tolerance in rheumatoid arthritis (RA) and other autoimmune diseases. The concept underpinning tolDC therapy is that it specifically targets the pathogenic autoimmune response while leaving protective immunity intact. Findings from human in-vitro and mouse in-vivo studies have been translated into the development of clinical grade tolDC for the treatment of autoimmune disorders. Recently, two tolDC trials in RA and type I diabetes have been carried out and other trials are in progress or are imminent. In this review, we provide an update on tolDC therapy, in particular in relation to the treatment of RA, and discuss the challenges and the future perspectives of this new experimental immunotherapy.

Publication metadata

Author(s): Hilkens CMU, Isaacs JD

Publication type: Review

Publication status: Published

Journal: Clinical & Experimental Immunology

Year: 2013

Volume: 172

Issue: 2

Pages: 148-157

Print publication date: 01/05/2013

Online publication date: 10/04/2013

Acceptance date: 14/11/2012

ISSN (print): 0009-9104

ISSN (electronic): 1365-2249

Publisher: WILEY-BLACKWELL

URL: http://dx.doi.org/10.1111/cei.12038

DOI: 10.1111/cei.12038

Share